Peter Lawrence, Cardurion Pharmaceuticals CEO
May 13, 2024 11:28 AM EDTUpdated May 16, 05:44 AM
R&D

Car­du­ri­on touts Phase 2 da­ta for PDE9 in­hibitor in heart fail­ure, plans for two more tri­als

Katherine Lewin

News Reporter

Car­du­ri­on Phar­ma­ceu­ti­cals tout­ed pos­i­tive da­ta for its heart fail­ure drug and an­nounced plans to pur­sue two more tri­als, three years af­ter the Mass­a­chu­setts biotech scored …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times